Sage therapeutics (NASDAQ:SAGE) is allegedly suing Biogen (NASDAQ:BIIB) due to the implementation of a standstill agreement following an unsolicited takeover bid valued at approximately $469 million.
The entire lawsuit, which was filed in Delaware court, is sealed. A court filing from Sage (